Ohsu Knight Cancer Institute
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Trials
229
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (196 trials with phase data)• Click on a phase to view related trials
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Locally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingDrug: Myc Inhibitor OMO-103
- First Posted Date
- 2025-07-29
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT07089940
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
- Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Interventions
- Procedure: Biospecimen CollectionProcedure: Lumbar Puncture
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT06895473
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Vaccine Responses in Patient with Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- Conditions
- Chronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular LymphomaMantle Cell LymphomaMultiple MyelomaPrimary Mediastinal Large B-Cell LymphomaSmall Lymphocytic Lymphoma
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT06784167
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial
- Conditions
- Clinical Stage IA Cutaneous Melanoma AJCC v8Clinical Stage IB Cutaneous Melanoma AJCC v8
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 1000
- Registration Number
- NCT06673095
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
- Conditions
- Advanced Breast CarcinomaAdvanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Advanced Ovarian CarcinomaAdvanced Pancreatic CarcinomaAdvanced Prostate CarcinomaStage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage III Prostate Cancer AJCC v8
- Interventions
- Procedure: BiopsyProcedure: Bone ScanProcedure: EchocardiographyProcedure: Multigated Acquisition ScanOther: Survey AdministrationProcedure: Biospecimen Collection
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06630325
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 46
- Next
News
Novel Nanoparticle Technology Enhances Ultrasound Cancer Treatment While Reducing Collateral Damage
• OHSU researchers have developed innovative nanoparticles that significantly improve high-intensity focused ultrasound cancer treatments by reducing required energy levels up to 100-fold, minimizing damage to surrounding healthy tissues. • The engineered nanoparticles feature surface bubbles that release energy when targeted with ultrasound, plus peptide coatings that help them adhere to tumors and deliver chemotherapy drugs directly to cancer cells. • In preclinical melanoma models, the combination therapy led to complete tumor elimination in some cases and improved survival beyond 60 days, demonstrating potential for treating hard-to-reach tumors with minimal side effects.